Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | RAD52 | P43351 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1008219 | 0.83 | KDM4E (0.52) | KDM4ETSHRPOLBPKMALDH1A1 | |
| SCHEMBL19315929 | 0.82 | KDM4E (0.50) | KDM4ETSHRPOLBPKMALDH1A1 | |
| Hydrochloric Acid SCHEMBL28802936 | 0.80 | KDM4E (0.48) | KDM4ETSHRPOLBPKMALDH1A1 | |
| SCHEMBL23545614 | 0.78 | KDM4E (0.47) | KDM4ETSHRPOLBPKMALDH1A1 | |
| SCHEMBL17176295 | 0.78 | KDM4E (0.45) | KDM4ETSHRPOLBPKMALDH1A1 | |
| SCHEMBL28803131 | 0.76 | KDM4E (0.44) | KDM4ETSHRPOLBPKMALDH1A1 | |
| SCHEMBL1006696 | 0.75 | KDM4E (0.52) | KDM4ETSHRPOLBPKMALDH1A1 | |
| SCHEMBL458012 | 0.75 | KDM4E (0.68) | KDM4ETSHRPOLBPKMALDH1A1 | |
| SCHEMBL5307853 | 0.75 | — | — | |
| SCHEMBL2821117 | 0.75 | KDM4E (0.68) | KDM4ETSHRPOLBPKMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100166819-A1 | Transforming Growth Factor Modulators | BIOGEN IDEC MA INC. A CORPORATION | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100166819-A1 | Transforming Growth Factor Modulators | ACVR1, TGFBR1, ACVRL1 | KDM4E 904/4885TSHR 674/4885POLB 4384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.